Biotech | August 23, 2021
Delfi liquid biopsy shows promise for reducing lung cancer deaths
When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
